Gene cloning of murine α-fetoprotein gene and construction of its eukaryotic expression vector and expression in CHO cells

Abstract

To clone the murine α-fetoprotein (AFP) gene, construct the eukaryotic expression vector of AFP and express in CHO cells, total RNA were extracted from Hepa 1–6 cells, and then the murine α-fetoprotein gene was amplified by RT-PCR and cloned into the eukaryotic expression vector pcDNA3. 1. The recombinant of vector was identified by restriction enzyme analysis and sequencing. After transient transfection of CHO cells with the vector, Western blotting was used to detect the expression of AFP. It is concluded that the 1.8 kb murine α-fetoprotein gene was successfully cloned and its eukaryotic expression vector was successfully constructed.

Keywords

gene cloning / α-fetoprotein gene / eukaryotic expression vector / CHO cells

References

[1] SchaferD F, SorrellM F. Hepatocellular carcinoma. Lancet, 1999, 353: 1253-1253

[2] TangZ Y. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol, 2001, 7: 445-445

[3] QinLX, TangZY. The prognostic significance of clinical and pathologica, 1 features in hepatocellular carcinoma. World Gastroenterol, 2002, 8: 193-193

[4] ZhangG, LongM, WuZ Z, et al.. Mechanical properties of hepatocellular carcinoma cells. World J Gastroenterol, 2002, 8: 243-243

[5] TangZ Y, SunF X, TianJ, et al.. Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential. World J Gastroenterol, 2001, 7: 597-597

[6] DeutschH F. Chemistry and biology of α-fetoprotein. Adv Cancer Res, 1991, 56: 253-253

[7] FoxH, KondiA, LinsellC A, et al.. The α-fetoprotein test in hepatocellular carcinoma. Lancet, 1970, 1: 411-411

[8] CoulieP G, WeynantsP, LehmannF, et al.. Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J Immunother, 1993, 14: 104-104

[9] BakkerA B, SchreursM W, BoerA J, et al.. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp. Med, 1994, 179: 1005-1005

[10] XiangR, PrimusF J, RuehlmannJ M, et al.. A dualfunction DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol, 2001, 167: 4560-4560

[11] BeiR, BudillonA, RealeM G, et al.. Cryptic epitopes on α-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res, 1999, 59: 5471-5471

[12] ButterfieldL H, KohA, MengW, et al.. Generation of human T cell responses to an HLA-A2. 1-restricted peptide epitope from αFetoprotein. Cancer Res, 1999, 59: 3134-3134

[13] ButterfieldL H, MengW S, KohA, et al.. T cell responses to HLA-A 0201-restricted peptides derived from α-fetoprotein. J Immunol, 2001, 166: 5300-5300

[14] VollmerC M, EilberF C, ButterfieldL H, et al.. αfetoprotein-specific immunotherapy for hepatocellular carcinoma. Cancer Res, 1999, 59: 3064-3064

[15] MengW S, ButterfieldL H, RibasA, et al.. α-fetoprotei-specific tumor immunity induced by plasmid primeadenovirus boost genetic vaccination. Cancer Res, 2001, 1: 8782-8782

[16] BocchiaM, BronteV, ColomboM P, et al.. Antitumor vaccination: where we stand. Haematologica, 2000, 85: 1172-1172

[17] AdaG L. The immunological principles of vaccination. Lancet, 1990, 335: 523-523

[18] WeinerD B, KennedyR C. Genetic vaccines. N Engl J Med, 1999, 341: 277-277

[19] RobinsonH L, TorresC A. DNA vaccines. Semin Immunol, 1997, 9: 271-271

[20] PardollD M, BeckerlegA M. Exposing the immunology of naked DNA vaccines. Immunity, 1995, 3: 165-165

[21] DonnellyJ J, UlmerJ B, ShiverJ W, et al.. DNA vaccines. Annu Rev Immunol, 1997, 15: 617-617

[22] BronteV, ApolloniE, RoncaR, et al.. Genetic vaccination with “self” tyrosinase—related protein 2 causes melanoma eradication ut not vitiligo. Cancer Res, 2000, 60: 253-253

[23] TutingT, GambottoA, DeLeoA, et al.. Induction of tumor antigen-specific immunity sing plasmid DNA immunization in mice. Cancer Gene Ther, 1999, 6: 73-73

[24] RosatoA, ZambonA, MilanG, et al.. CTL response and rotection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum Gene Ther, 1997, 8: 1451-1451

[25] GrahamR A, BurchellJ M, BeverleyP, et al.. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer, 1996, 65: 664-664

[26] ConryR M, LoBuglioA F, LoechelF, et al.. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther, 1995, 2: 33-33

[27] CarninciP, HayashizakiY. High-efficiency full-length cDNA cloning. Meth Enzymol, 1999, 303: 19-19